BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 34845968)

  • 41. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
    Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stem/progenitor cell marker expression in clear cell renal cell carcinoma: a potential relationship with the immune microenvironment to be explored.
    Yoon JY; Gedye C; Paterson J; Ailles L
    BMC Cancer; 2020 Apr; 20(1):272. PubMed ID: 32245446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.
    Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB
    Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.
    Wu XR; Sha JJ; Liu DM; Chen YH; Yang GL; Zhang J; Chen YY; Bo JJ; Huang YR
    Eur J Surg Oncol; 2013 Jan; 39(1):100-6. PubMed ID: 23102595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
    Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
    Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.
    Xu WH; Shi SN; Wang J; Xu Y; Tian X; Wan FN; Cao DL; Qu YY; Zhang HL; Ye DW
    Med Sci Monit; 2019 Dec; 25():9458-9470. PubMed ID: 31825950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NUF2 is correlated with a poor prognosis and immune infiltration in clear cell renal cell carcinoma.
    Zheng B; Wang S; Yuan X; Zhang J; Shen Z; Ge C
    BMC Urol; 2023 May; 23(1):82. PubMed ID: 37138262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel risk signature based on liquid-liquid phase separation-related genes reveals prognostic and tumour microenvironmental features in clear cell renal cell carcinoma.
    Lu Q; Xi P; Xu S; Zhang Z; Gong B; Liu J; Zhu Q; Sun T; Zhu S; Chen R
    Aging (Albany NY); 2024 Mar; 16(7):6118-6134. PubMed ID: 38546385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Integrative analysis of TRPV family to prognosis and immune infiltration in renal clear cell carcinoma.
    Gong Z; Xie J; Chen L; Tang Q; Hu Y; Xu A; Wang Z
    Channels (Austin); 2022 Dec; 16(1):84-96. PubMed ID: 35389815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrated analysis of tertiary lymphoid structures and immune infiltration in ccRCC microenvironment revealed their clinical significances: a multicenter cohort study.
    Wang YQ; Chen WJ; Zhou W; Dong KQ; Zuo L; Xu D; Chen JX; Chen WJ; Li WY; Liu ZC; Jiang ZY; Tang YF; Qin YX; Wang LH; Pan XW; Cui XG
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Downregulation of
    Wang T; Xie F; Li YH; Liang B
    Future Oncol; 2021 Dec; 17(36):5033-5044. PubMed ID: 34704468
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of a risk model for prognostic and therapeutic prediction in renal cell carcinoma based on infiltrating M0 cells.
    Xin S; Su J; Li R; Cao Q; Wang H; Wei Z; Wang C; Zhang C
    Sci Rep; 2024 Jun; 14(1):13390. PubMed ID: 38862642
    [TBL] [Abstract][Full Text] [Related]  

  • 53. miR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN/SMAD4 expression.
    Ma Q; Peng Z; Wang L; Li Y; Wang K; Zheng J; Liang Z; Liu T
    Int J Oncol; 2016 Dec; 49(6):2589-2599. PubMed ID: 27779660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma.
    Fu L; Bao J; Li J; Li Q; Lin H; Zhou Y; Li J; Yan Y; Langston ME; Sun T; Guo S; Zhou X; Chen Y; Liu Y; Zhao Y; Lu J; Huang Y; Chen W; Chung BI; Luo J
    Front Immunol; 2022; 13():1021935. PubMed ID: 36248876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis.
    Wang Y; Chen L; Wang G; Cheng S; Qian K; Liu X; Wu CL; Xiao Y; Wang X
    J Cell Physiol; 2019 Jul; 234(7):10225-10237. PubMed ID: 30417363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. hZIP1 that is down-regulated in clear cell renal cell carcinoma is negatively associated with the malignant potential of the tumor.
    Dong X; Kong C; Zhang Z; Liu X; Zhan B; Chen Z; Shi D
    Urol Oncol; 2014 Aug; 32(6):885-92. PubMed ID: 24878177
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
    DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Novel Prognostic Predictor of Immune Microenvironment and Therapeutic Response in Kidney Renal Clear Cell Carcinoma based on Necroptosis-related Gene Signature.
    Chen W; Lin W; Wu L; Xu A; Liu C; Huang P
    Int J Med Sci; 2022; 19(2):377-392. PubMed ID: 35165523
    [No Abstract]   [Full Text] [Related]  

  • 59. Co-expression Network Analysis Identifies Fourteen Hub Genes Associated with Prognosis in Clear Cell Renal Cell Carcinoma.
    Chen JY; Sun Y; Qiao N; Ge YY; Li JH; Lin Y; Yao SL
    Curr Med Sci; 2020 Aug; 40(4):773-785. PubMed ID: 32862390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of IL20RB as a Novel Prognostic and Therapeutic Biomarker in Clear Cell Renal Cell Carcinoma.
    Guo H; Jiang S; Sun H; Shi B; Li Y; Zhou N; Zhang D; Guo H
    Dis Markers; 2022; 2022():9443407. PubMed ID: 35299868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.